Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
Lupus: Closer to a Cause?
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
The Rheumatologist’s Role in Sarcoidosis
Rheumatologists are uniquely positioned to care for patients with sarcoidosis. Here are insights into the condition, its treatment and more.
Helping Patients with SLE Thrive
Dr. Laurent Arnaud highlighted the latest information on systemic lupus erythematosus (SLE), including genetics, technology, treat to target, and promising findings for pulse therapy in his session at EULAR 2024.
What’s New in Polymyalgia Rheumatica?
Should all patients with polymyalgia rheumatica (PMR) have a vascular ultrasound assessment? What treatments are the safest and most efficacious for patients with PMR? Frank Buttgereit, MD, answered these questions and highlighted the latest research on PMR in this session at EULAR 2024.
Coagulation Education: Treatment Options for Antiphospholipid Syndrome
Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.
The High Stakes of Brain, Ear, Eye Syndromes
Experts detailed the diagnosis and treatment of two patients with Susac syndrome, a brain, ear, eye syndrome. They also provided insights into the complexities of these conditions, why they are difficult to diagnose and key points for practicing rheumatologists.
The Truth About Remote Care
Long wait times for appointments, the rheumatologist shortage in rural areas—does telehealth solve some aspects of access to care for rheumatology patients? Three experts highlighted the data on remote care, unveiling surprising truths and misconceptions.
What’s New in Treatment: IgA Vasculitis & IgA Nephropathy
Dr. Jens Thiel provided a detailed overview of specific treatments for patients with immunoglobulin A (IgA) vasculitis and IgA nephropathy, highlighting treatments in early clinical trials.
CAR-T Cell Therapy in Autoimmune Disease: The Next Frontier
Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.